Maravai Lifesciences Expands Its Contract Development and Manufacturing Organization (CDMO) Capabilities at Trilink Biotechnologies

Maravai Lifesciences | August 25, 2020

Maravai LifeSciences, a global provider of life science reagents and services to researchers and biotech innovators, is expanding its contract development and manufacturing organization (CDMO) capabilities at TriLink BioTechnologies for the second time in less than a year. The expansion is expected to be completed in the first quarter of 2021 and will increase TriLink's small molecule manufacturing capacity with a focus on additional scale-up of CleanCap®, its proprietary messenger RNA (mRNA) capping technology, for global mRNA vaccine and therapeutic programs. To further address the increasing demand for mRNA development and clinical programs, the company is currently completing the construction of its plasmid DNA production facility as well. Last November, TriLink opened their new headquarters in San Diego, CA and expanded mRNA and small molecule capacity as it opened five Current Good Manufacturing Practice (cGMP) suites. The current investment will further expand the operation with an additional three cGMP suites and four cGMP manufacturing support suites.

Spotlight

Growing at a faster pace, in comparison with the previous years, the Indian biotech industry witnessed YoY growth of 57.14 per cent in FY16; the total industry size stood at US$ 11 billionby FY16 and is estimated to reach US$ 11.6 billion by FY17.
Fast-paced growth is likely to continue; the industry is expected to increase in size to US$ 11.6 billion by 2017, driven by a range of factors such as growing demand, intensive R&D activities and strong government initiatives.


Other News
MEDICAL

NuclixBio Announces a Collaborative Research Agreement with PharmAbcine

NuclixBio | March 15, 2022

NuclixBio Inc., a South Korean biotech company that focuses on research and development of mRNA therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA™' to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies. These novel therapeutics will express antibodies intracellularly to target human TIE2 receptors present on epithelial cells. The newly developed drugs based on circular mRNA can have a better therapeutic effect compared to conventional linear mRNA-based therapies due to the proven prolonged half-life of circular mRNA. The circular form of mRNA also allows ribosomes, the particles that function to synthesize proteins, to continuously circulate around the loop of mRNA to produce a greater quantity of polypeptides, including therapeutic antibodies. Thus, the elongated half-life and therapeutic efficiency can improve patient convenience in terms of drug administration routes and intervals. This partnership will give both parties an extraordinary opportunity to utilize advanced proprietary technologies and provide tremendous growth opportunities, We are thankful for this strategic partnership and are looking forward to developing breakthrough therapeutic approaches that can both expand our pipeline and help patients with unmet medical needs." Dr. Jin-San Yoo, CEO of PharmAbcine. The distinctive feature of our mRNA platform is that we circularize the linear precursor RNAs and make them into circular mRNAs. This method allows more desirable protein expressions in in vivo settings, with higher stability and efficiency. Our ringRNA™ can be used in a wide range of indications, We are thrilled to have entered this collaborative agreement with PharmAbcine, one of the leading antibody-based therapeutic companies. We hope our collaborative work will show many possibilities and result in the rapid development and expansion of the pipeline assets." Dr. Hoyoung Kang, CEO of NuclixBio. About PharmAbcine Inc. PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, pulmonology, to renal pathology. PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state-of-the art antibody generation services. About NuclixBio NuclixBio, Inc. is a pre-clinical stage biotech company focusing on early-stage research and development of intracellularly targeted nucleic acid therapeutics that are based on proprietary platform technologies. With its own circular mRNA platform ringRNA™, NuclixBio has established additional strong therapeutics platform such as Ribo-TaP™ and Ribo-grAb™, and is currently developing targeted oncology and immuno-oncology therapeutics assets.

Read More

INDUSTRIAL IMPACT

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Willow Biosciences Inc. | February 01, 2022

Willow Biosciences Inc. a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, announced that it will host a webcast investor presentation on Thursday, February 3rd at 2:00 PM EST. During the webcast, Willow's President and Chief Executive Officer Trevor Peters will provide a presentation through a PowerPoint discussion that will cover key areas of Willow's business. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal. About Willow Biosciences Inc. Willow is a leading biotechnology company that develops and produces high-purity, plant derived ingredients for the consumer care, food and beverage, and pharmaceutical markets. Willow's FutureGrown™ biotechnology platform allows scale production of pure, consistent, and sustainable product to benefit both B2B and B2C customers. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products for both the consumer and pharmaceutical industries.

Read More

INDUSTRIAL IMPACT

Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech

Cyclica Inc. | February 10, 2022

Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs). Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Perturba is taking this challenge on by integrating Cyclica’s comprehensive AI-augmented proteome-wide drug design technology with two first-in-class live cell-based assays from the Stagljar Lab. With this integrated AI-augmented drug design and empirical phenotypic approach, Perturba is developing precision therapies that modulate PPIs and PPI-mediated biological processes with a focus on difficult-to-treat cancers. Perturba will initially focus on advancing two EGFR triple mutant inhibitors for non-small cell lung cancer, and four programs targeting small GTPases for various intractable cancers. Naheed Kurji, Co-Founder, CEO and President of Cyclica indicates that “More than half of all human disease-related proteins are considered undruggable using conventional approaches. As a result, patients suffering from life threatening diseases are left waiting for treatment. What others view as “undruggable”, we see as potential. Perturba represents an important franchise in the pursuit of our cancer strategy. We’re so excited to partner with Professor Stagljar and the world class Stagljar Lab in driving forward our shared vision.” "over the past two years, my lab has developed two high impact, live cell-based technologies for studying protein-protein interactions and identifying novel drug molecules – MaMTH-DS and SIMPL. Combining these two technologies with Cyclica’s world-class AI-drug design approach will usher in a new way to conduct drug discovery for highly intractable targets in an unprecedented way at scale. I’ve known Naheed and the team at Cyclica for years and jointly have shown multiple proof points using our platforms with a program targeting an osimertinib resistant EGFR triple mutant that we will be progressing in Perturba, and a program targeting an oncogenic KRAS in a separate collaboration that gave us confidence to target other small GTPases in Perturba.” Dr. Igor Stagljar, Professor at University of Toronto’s Temerty Faculty of Medicine and Principal Investigator at the Donnelly Centre Seasoned drug developer Rick Panicucci, PhD, SVP at BridgeBio Pharma and a long time advisor at Cyclica has been appointed as non-executive Chairman of Perturba to help oversee the company's strategy. Su Dharmawardhane Flanagan, PhD, Tony Hunter, PhD and Ming Tsao, MD, have been appointed to Perturba’s Scientific Advisory Board. Cyclica will provide initial funding for Perturba and will seek external funding from strategic partners as required. “I’ve been involved in drug discovery & development for over 25 years. What I can say with certainty is that the way things will be done going forward is going to be very different from how it was done before. I’ve been an advisor at Cyclica for 6 years and have witnessed first hand the power of AI and data-first approaches to drive drug discovery fast and with quality. Now, with Perturba and integrating AI drug design and phenotypic assays opens a whole new way of design-make-test-analyze at scale for target classes that have been ignored for too long,” shares Panicucci. About Perturba An integrated oncology focused biotech company for unaddressable and undrugged targets. Founded in 2021 as a venture between Cyclica and the Stagljar Lab at the University of Toronto, Perturba integrates Cyclica’s AI-augmented drug discovery platform with sensitive, live-cell drug screening assays, MaMTH-DS and SIMPL from the Stagljar lab. Perturba is developing precision therapies at scale that modulate PPIs and PPI-mediated biological processes. About Cyclica Cyclica advances molecules that embrace the complexity of disease. A neo-biotech whose work spans dozens of collaborations with large pharma, biotech and several joint ventures. We are a passionate team of biotech and pharma professionals, biologists, chemists, and computer scientists who live and labour at the intersection of our collective expertise. About the Stagljar Lab and the Donnelly Centre The Stagljar lab at the University of Toronto is one of the world leading labs in the field of proteomics/chemical genomics, developing high-throughput technologies to facilitate the study of the protein-protein interactions (PPIs) of various human membrane proteins involved in cancer and rare genetic diseases such as cystic fibrosis. The Stagljar lab is currently directing major proteomics/chemical genomics projects to map how integral membrane proteins interact to produce either healthy or diseased cells, to identify novel therapeutic targets, and to screen for novel drugs using artificial intelligence platforms, in particular to target lung, colon, breast and pancreatic cancer. In close collaboration with medicinal chemists and clinical investigators, the Stagljar lab investigates the molecular mechanisms behind challenging, unexplained observations on drugs and on pathological events.

Read More

CELL AND GENE THERAPY

Taysha Gene Therapies Added to the Nasdaq Biotechnology Index

Taysha Gene Therapies | December 16, 2021

Taysha Gene Therapies Inc. a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced that it has been added to the Nasdaq Biotechnology Index in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021. “We are pleased to announce Taysha’s inclusion in the Nasdaq Biotechnology Index. As we continue to advance our broad pipeline and execute on our near-term clinical and regulatory milestones, inclusion in this index will enhance our visibility and expand awareness of our story with investors.” RA Session II, President, Founder and CEO of Taysha The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December. About Taysha Gene Therapies Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.

Read More

Spotlight

Growing at a faster pace, in comparison with the previous years, the Indian biotech industry witnessed YoY growth of 57.14 per cent in FY16; the total industry size stood at US$ 11 billionby FY16 and is estimated to reach US$ 11.6 billion by FY17.
Fast-paced growth is likely to continue; the industry is expected to increase in size to US$ 11.6 billion by 2017, driven by a range of factors such as growing demand, intensive R&D activities and strong government initiatives.

Resources